SIMANGELE TSHUMA: Open Payments
NPI 1285251041 · BURLESON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,626 in 38 payments from 17 companies in 2025. Trend: 2023 $2,745 · 2024 $2,158 · 2025 $1,626
Long term medical supply or device loan: $1,000Food & beverage: $626
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 13 | $1,037 |
| Regeneron Healthcare Solutions, Inc. | 3 | $87 |
| Eisai Inc. | 3 | $74 |
| Incyte Corporation | 3 | $72 |
| Merck Sharp & Dohme LLC | 2 | $58 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | 2 | $46 |
| AstraZeneca Pharmaceuticals LP | 2 | $39 |
| ARRAY BIOPHARMA INC | 1 | $29 |
| Aveo Pharmaceuticals, Inc. | 1 | $25 |
| Blue Earth Diagnostics | 1 | $23 |
Products named: KISQALI, Lenvima, KEYTRUDA, LYNOZYFIC, MONJUVI, Odomzo, LIBTAYO, XALKORI.
Industry payments across TX — which companies pay providers there.
